Transforming diagnosis and therapy of immune-Mediated diseases.
Transdisciplinary consortium to focus on common biomarkers in Ulcerative Colitis and Atopic Dermatitis.
Radboudumc collaborates with 25 European partners on dissecting common disease mechanisms of Ulcerative Colitis and Atopic Dermatitis in the new research project ImmUniverse, aimed at improving diagnostic and therapeutic options for patients living with these conditions. Through molecular and immune profiling techniques, the team will identify signatures of biomarkers and mechanistic principles which reveal information on disease severity and progression enabling personalised therapy decisions for each patient at the right time. The project was granted a budget of EUR 31 million provided by the Innovative Medicines Initiative (IMI 2), a joint initiative of the European Union and the EFPIA (European Federation of Pharmaceutical Industries and Associations), and is coordinated by Humanitas University in Milan.
Immune-mediated inflammatory diseases (IMIDs) are an increasing medical burden in industrialised countries worldwide. They are characterised by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which often cannot be adequately tailored to individual patients. Hence, an in-depth understanding of this heterogeneity and the biomarkers which predict disease control and therapy response over time are important prerequisites for future precision medicine strategies in IMIDs. The pathogenic components (“omics”) responsible for the disease outcome in each individual patient, i.e. environment, genes, gut microbiota or the immune system, are remarkably multifactorial, with thousands of constituents all interacting with and impacting on each other.
ImmUniverse has been formed as a European transdisciplinary consortium to tackle the unmet needs and pave the way towards a truly personalised disease understanding of two different IMIDs: Ulcerative Colitis and Atopic Dermatitis. Irma Joosten, local coordinator: "Through a unique collaboration between the departments dermatology, Elke de Jong, Ellen van den Bogaard), Gastroenterology Frank Hoentjen, and Medical Immunology, Hans Koenen, all theme Inflammatory diseases, we will be able, together with our consortium partners, to embark on an extensive cross-disease -omics quest, where we will systematically compare profiles and interactions between recirculating immune cells and the respective tissue microenvironment. In a prospective study, and unlike previous studies in the field, we will specifically compare signatures from the same individual over time, capturing the full range of disease activity. The novel, circulating (immune)biomarker assays are expected to improve diagnosis, inform about disease severity and progression early in the clinical course, and enable treatment response and remission monitoring."
Related news items
The Postdoctoral Networking Tour in artificial intelligence2 July 2020
You are a postdoctoral researcher in the field of artificial intelligence? The Postdoc-NeT-AI offers you the opportunity to participate in one week of on-site visits to leading German universities, research institutes and companies. Apply now to this year's tour until 16 August 2020.read more
Register for Phd courses via gROW What does this mean for you?2 July 2020
From now on you can arrange everything related to the general RU PhD courses via gROW. Because of this there will be some changes in the registration! What does this mean for you?read more
Experts on metabolic diseases still an unknown major problem...1 July 2020
Six Dutch UMCs and a patient association contribute to treating and solving this major, often unknown, problem. Timely detection of metabolic diseases is vital. Therefore, Radboudumc is also part of the consortium “United for Metabolic Diseases”.read more
Radboud Pluim for Lionne Ekers ambassador for the RIMLS institute30 June 2020
Lionne Ekers received the Radboudpluim for her special merits for the Radboudumc. She is a born ambassador for our Institute.read more
Stefan Listl member Lancet Commission on Oral Health29 June 2020
In recognition of the global public health importance, woeful neglect of oral diseases, and the need for a broader understanding and commitment to global oral health within medicine and global health agendas, The Lancet recently established a Commission on Oral Health.read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection29 June 2020
In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.read more